English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In the absence of any effective vaccine against human immunodeficiency virus  (HIV), current anti-retroviral drugs may be suitable for pre-exposure prophylaxis  (PrEP). Previous large clinical trials showed that PrEP reduced HIV infection in  high-risk populations. Emtricitabine/tenofovir (FTC/TDF) may be a suitable agent  for PrEP. FTC/TDF PrEP efficacy was evaluated using a highly pathogenic  simian/human immunodeficiency virus (SHIV) in a non-human primate model of AIDS,  the SHIV-KS661c/cynomolgus monkey model. Double oral administration of FTC/TDF  (20/30 mg/kg), at 24 h and a few minutes prior to exposure, completely protected  2/3 monkeys from infection. Interestingly, a single oral administration 2 weeks  before viral exposure moderately rescued CD4 cells, although the data did not  reach statistical significance. These results are consistent with previous primate  studies and with recent clinical data.

japanese journal of infectious diseases

Double Oral Administration of Emtricitabine/Tenofovir Prior to Virus Exposure Protects against Highly Pathogenic Simian/Human Immunodeficiency Virus Infection in Macaques